Body Composition changes after Testosterone Replacement Therapy following Spinal Cord Injury and Aging:A Mini Review by Nightingale, Tom et al.
        
Citation for published version:
Nightingale, T, Moore, P, Harman, J, Khalil, R, Gill, R, Castillo, T, Adler, R & Gorgey, A 2018, 'Body Composition
changes after Testosterone Replacement Therapy following Spinal Cord Injury and Aging: A Mini Review', The
Journal of Spinal Cord Medicine , vol. 41, no. 6, pp. 624-636. https://doi.org/10.1080/10790268.2017.1357917
DOI:
10.1080/10790268.2017.1357917
Publication date:
2018
Document Version
Peer reviewed version
Link to publication
This is an Accepted Manuscript of an article published by Taylor and Francis in The Journal of Spinal Cord
Medicine on 3 August 2017, available online: https://doi.org/10.1080/10790268.2017.1357917
University of Bath
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 13. May. 2019
1 
 
Body Composition changes after Testosterone Replacement Therapy following Spinal Cord 1 
Injury and Aging. A Mini Review 2 
 3 
  4 
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Abstract 1 
CONTEXT: Hypogonadism is a male clinical condition in which the body does not produce 2 
enough testosterone.  Testosterone plays a key role in maintaining body composition, bone 3 
mineral density, sexual function, mood, erythropoiesis, cognition and quality of life. 4 
Hypogonadism can occur due to several underlying pathologies during aging and in men with 5 
physical disabilities, such as spinal cord injury (SCI). This condition is often under diagnosed 6 
and as a result, symptoms undertreated.  7 
METHODS: In this mini-review, we propose that testosterone replacement therapy (TRT) might 8 
be a viable strategy to improve lean body mass (LBM) and fat mass (FM) in men with SCI.  9 
EVIDENCE SYNTHESIS: Supplementing the limited data from SCI cohorts with consistent 10 
findings from studies in non-disabled aging men, we present evidence that, relative to placebo, 11 
transdermal TRT can increase LBM and reduce FM over 3 – 36 months. The impact of TRT on 12 
bone mineral density and metabolism is also discussed, with particular relevance for persons 13 
with SCI. Moreover, the risks of TRT remain controversial and pertinent safety considerations 14 
related to transdermal administration are outlined.  15 
CONCLUSION: Further research is necessary to help develop clinical guidelines for the specific 16 
dose and duration of TRT in persons with SCI. Therefore, we call for more high-quality 17 
randomized controlled trials to examine the efficacy and safety of TRT in this population, who 18 
experience an increased risk of cardiometabolic diseases as a result of deleterious body 19 
composition changes after injury.   20 
 21 
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Introduction: 1 
Sarcopenia refers to the loss of skeletal muscle mass with age and plays an important role in the 2 
etiology of functional and mobility impairments in older adults (1). It has been suggested that 3 
persons with spinal cord injury (SCI) represent a model of accelerated sarcopenia or premature 4 
aging (2). Following SCI, as a result of paralysis and disuse, considerable atrophy of lean mass 5 
occurs below the level of injury within the first 6 – 12 months (3, 4). Accelerated loss of lean 6 
mass has also been reported above the level of injury (5), which is likely a factor of overall 7 
reduced physical activity observed in this population (6). Besides the loss of lean mass, the 8 
quality of skeletal muscle that remains below the level of the injury also deteriorates. In persons 9 
with SCI, adipose tissue has been shown to accumulate within and between muscle groups (7, 8) 10 
and the accumulation of intramuscular fat (IMF) has previously been linked with impaired 11 
glucose tolerance (9, 10). While the specific mechanisms regarding the impact of IMF on 12 
skeletal muscle metabolism remains to be elucidated, studies have suggested IMF impairs blood 13 
flow and releases pro-inflammatory mediators resulting in local inflammation (11, 12). Such 14 
changes within the skeletal muscle of persons with SCI have profound implications in the 15 
progression of certain chronic diseases, such as type 2 diabetes mellitus (T2DM) and 16 
cardiovascular disease (CVD).  17 
 18 
Collectively, the loss of lean body mass (LBM) is responsible for the decreased resting metabolic 19 
rate (RMR) reported in persons with SCI (13). Such reductions in energy expenditure may 20 
contribute to an energy surplus, which if sustained, will eventually lead to increased fat mass 21 
(FM) accumulation. Consequently, best available estimates suggest that up to two thirds of the 22 
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SCI population are overweight or obese (14). Besides an increased prevalence of obesity, the 1 
location of adipose tissue accumulation is also different in persons with SCI. Edwards et al, (15) 2 
found that persons with SCI had 58% more visceral adipose tissue (VAT; quantified by 3 
computed tomography) than waist circumference-matched able-bodied controls. The 4 
accumulation of VAT is of particular importance as it has been linked with impaired 5 
carbohydrate and lipid metabolism in persons with SCI (16) and exhibits a more pro-6 
inflammatory profile (17). Even modest subclinical elevations in inflammatory cytokines 7 
(interleukin-6) and acute phase proteins (C-reactive protein) may increase the risk of developing 8 
cardiovascular disease (18, 19). Epidemiological evidence suggests that individuals characterized 9 
as low muscle/high fat mass have an elevated all-cause mortality risk compared to other body 10 
composition subtypes (20). To mitigate such mortality and cardiometabolic disease risks, it is 11 
important to identify appropriate strategies that could facilitate the restoration of favorable body 12 
composition, particularly in vulnerable populations such as persons with SCI.  13 
 14 
Testosterone replacement therapy (TRT) has been identified as an effective strategy in restoring 15 
LBM and decreasing FM in different clinical population. Testosterone (T) is an important 16 
anabolic hormone that influences muscle, bone, adipose tissue, hematopoiesis, sexual function, 17 
mood, quality of life and cardiovascular disease risk factors (21). The majority of testosterone 18 
production takes place in the Leydig cells of the testes. Each day males produce 3 – 10 mg of 19 
endogenous T; approximately 60-70% of which circulates tightly bound to sex hormone binding 20 
globulins (SHBG), loosely bound to albumin (30-40%), or free (0.5-2%) (22). The anabolic 21 
effects of androgens on skeletal muscle have been a source of controversy for decades. 22 
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Increasing serum T can increase LBM via hypertrophy of both type I and II skeletal muscle 1 
fibers (23). T acts upon androgen receptors; activating transcription factors in the nucleus of the 2 
cell thereby increasing protein synthesis (24), and promoting differentiation of pluripotent 3 
mesenchymal cells into the myogenic lineage and inhibiting differentiation into the adipogenic 4 
lineage (25). Besides the indirect effect of TRT modulating FM through increased energy 5 
expenditure caused by skeletal muscle hypertrophy, TRT may also have a direct effect on 6 
adipose tissue metabolism. De Pergola et al, (26) demonstrated that T promotes lipolysis and 7 
reduces fatty acid synthesis, with these effects being more evident in VAT.  8 
 9 
In older men, the gradual decrease of serum T concentrations, known as late onset hypogonadism 10 
(levels of total serum T; < 6.9 nmol/L or 200 ng/dl), occurs at the same time in life as sarcopenia 11 
and osteoporosis (27-29). About 60% of men over the age of 65 years have low serum T levels 12 
(< 10.4 nmol/L or 300 ng/dl) (30). Such hormonal changes may contribute to muscle loss and 13 
increased FM with aging (31-33). Similarly, previous research indicates between 46 – 60% of 14 
men with SCI have low serum T levels (34, 35). Body composition changes with aging are 15 
accelerated in persons with SCI; the etiology of which could be due to the combination of low 16 
serum T and reduced physical activity [which also declines with aging (36)]. T levels are also 17 
inversely related to time since injury (34, 37) and persons with motor complete SCI have a 18 
greater prevalence of low serum T than persons with motor-incomplete SCI (38). Interestingly, 19 
reduced physical activity levels have been associated with longer time since injury (39) and 20 
motor-complete injuries (6). Although cause and effect may be difficult to define, the 21 
combination of reduced physical activity, low serum T, and aging in persons with complete SCI 22 
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may further exacerbate adverse body composition changes and associated cardiometabolic 1 
parameters.  2 
 3 
Current therapeutic methods for TRT are oral formulations, intramuscular injections or 4 
transdermal delivery. Oral T has a high first-pass liver metabolism and certain oral formulations 5 
therefore have significant liver toxicity (40), a notable limitation of this delivery method.  6 
Although intramuscular injections produce a high level of serum T initially, short-acting T esters 7 
(i.e. Enanthate, Cypionate and Proprionate) decline rapidly towards the end of the injection 8 
cycle. Whereas, injectable T-undecanoate (i.e. Aveed) has been shown to elevate serum T for ≥ 9 
10 weeks following injection (41). However, this mini-review aims to primarily focus on 10 
transdermal (i.e. patch or gel) TRT administration for the following reasons; (i) elevated patient 11 
compliance compared to other methods of delivery and convenience of administration (42), (ii) 12 
effective at sustaining plasma T levels over 24 hours in a way that mimics the human body’s 13 
natural T production cycle (43) and, (iii) high bioavailability. The aim of this review is to discuss 14 
the impact of transdermal TRT on body composition changes, with relevance to persons with 15 
SCI. Other potential health benefits derived from TRT; preserved bone mineral density, 16 
maintenance of basal metabolic rate, and improved metabolic regulation will also be discussed. 17 
Lastly, we aim to discuss the safety of TRT and considerations for its application in persons with 18 
SCI. 19 
 20 
Methods 21 
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Data sources and searches 1 
To examine the effects of transdermal TRT on body composition parameters, a scoping review 2 
of the literature was performed using online databases [MEDLINE (PubMed) and Google 3 
Scholar] to identify relevant articles. Reference lists from identified studies were also scrutinized 4 
to retrieve other appropriate papers.  5 
 6 
Study inclusion criteria  7 
Studies included in this scoping review were required to meet the following criteria: (i) study 8 
participants [males with SCI and able-bodied elderly men (either hypogonadal or with low serum 9 
T concentrations], (ii) sample size (n ≥ 20 in T treatment group) to ensure a degree of statistical 10 
confidence in the findings, (iii) transdermal delivery of T (i.e. patch or gel) and, (iv) LBM or FM 11 
measured by dual-energy X-ray absorptiometry (DXA).  12 
 13 
Data synthesis and analysis  14 
The second author extracted descriptive and outcome data from the included studies, which were 15 
then fact-checked by the primary author. This scoping review identified 14 and 13 studies that 16 
reported the effect of TRT on LBM and FM, respectively. These studies are organized via TRT 17 
dosage with: duration of therapy, vehicle of delivery (i.e. gel or patch), participant characteristics 18 
and comparative placebo responses (LBM; Table 1, FM: Table 2). The duration of treatment and 19 
dosage ranged from 3 – 36 months and 2.5 – 10 mg/day, respectively. Mean ± SD changes (Δ) in 20 
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LBM and FM were extracted from the identified studies. These data were pooled to provide a 1 
qualitative interpretation of previous findings. Weighted means were calculated in Microsoft 2 
Excel to account for differences in sample size between studies using the following formula: 3 
∑n*Δx̅/∑n, where ∑ = the sum of, n = number of participants in each study and, Δx̅ = mean 4 
change in outcome of each study.  Δ in LBM and FM were separated via dose (≤ 5 mg or > 5 5 
mg) and compared to placebo responses, Fig. 1A and 3A, respectively. To better understand the 6 
impact of therapy duration and treatment delivery vehicle on Δ in LBM and FM, only studies 7 
that used doses ≤ 7.5 mg/day were pooled for analysis (Fig. 2A & C; Fig. 4A & C). This is 8 
because higher doses (10 mg/day) were only administered for a shorter period of time (3 – 6 9 
months) and predominantly in the gel format (Table 1), which would have impacted the analysis. 10 
Scatterplots are also displayed with polynomial lines of best fit to better display the fluctuations 11 
in individual study data for the impact of TRT dosage and duration of therapy.  12 
 13 
Impact of transdermal testosterone replacement therapy on body composition   14 
While transdermal TRT may offer a logical and effective strategy to counteract deleterious body 15 
composition changes post SCI, ambiguity currently remains about the correct dose and duration 16 
of treatment.  To the best of our knowledge, there is only one small-scale clinical trial that has 17 
assessed the safety and efficacy of TRT in men with SCI (44). In light of this we also drew upon 18 
randomized controlled trials in able-bodied elderly men (either hypogonadal or with low serum T 19 
concentrations) to help inform considerations pertaining to the most appropriate dose and 20 
duration of TRT to increase LBM and reduce FM in persons with SCI.  The baseline serum T 21 
inclusion criterion used in the studies analyzed in the body composition section of this mini-22 
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review (Tables 1 & 2, range < 7.3 – 15.0 nmol/L) is comparable to values (< 11.3 nmol/L) 1 
shown in more than 43% of persons with SCI (38). Therefore, in the absence of SCI data, elderly 2 
men represent a similar population of interest. Previous reports also suggest that persons with 3 
SCI experience a state of pre-mature aging (2). Recent data suggests testicular function was 4 
normal in men with SCI compared to able-bodied controls, confirming the absence of primary 5 
testicular dysfunction in this population (45). Therefore, hypogonadism in men with SCI is 6 
secondary to pituitary-hypothalamic dysfunction. Secondary hypogonadism is associated with 7 
obesity (46). However, the etiology of low T in aging men represents a mixture of both primary 8 
and secondary hypogonadism components (47). Nevertheless, studying the effects of transdermal 9 
applications of TRT in elderly men is likely to reflect clinically on men with SCI.   10 
 11 
[PLEASE INSERT TABLE 1 ABOUT HERE] 12 
Hildreth et al, (48)  13 
McNicholas et al, (40) 14 
Wang et al, (49) 15 
Steidle et al, (50) 16 
Frederiksen et al, (51) 17 
Magnussen et al, (52) 18 
Srinivas-Shankar et al, (53) 19 
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Behre et al, (54) 1 
Kenny et al, (55) 2 
Bauman et al, (44) 3 
Snyder et al, (56) 4 
Wang et al, (57) 5 
Storer et al, (58) 6 
Wang et al, (49) 7 
McNicholas et al, (40) 8 
Steidle et al, (50) 9 
Bhasin et al, (59) 10 
 11 
 12 
Lean body mass 13 
Twelve months of TRT (by testosterone patch) restored serum total T to physiological levels in 14 
persons with SCI and resulted in concurrent improvements in total LBM (3.5 kg) (44). This 15 
considerable increase in LBM was higher than values reported in elderly hypogonadal men. An 16 
explanation for this is that persons with SCI have a greater potential to increase LBM due to the 17 
extreme loss of LBM post SCI. However all TRT studies, irrespective of dose, improved LBM 18 
12 
 
(range, 0.7 – 2.7 kg).  Participants in the majority of these studies were instructed to continue 1 
with their normal lifestyle behaviors rather than perform a concurrent targeted exercise program. 2 
Larger doses resulted in greater increases in LBM, with the polynomial line of best fit suggesting 3 
the best dose is ~ 8 mg/day (Fig. 1B). However, it is difficult to draw conclusions regarding the 4 
most appropriate dose, as numerous studies titrated the dose of TRT over time to maintain 5 
measured serum T within a safe physiological range. Therefore, without access to individual data 6 
it is not possible to conduct a comprehensive statistical analysis. 7 
 8 
[PLEASE INSERT FIGURE 1 ABOUT HERE] 9 
 10 
The weighted means (± SD) show a small increase (0.5 kg) between TRT for ≥12 months as 11 
opposed to 3 months. Relatively few studies have administered transdermal TRT for more than a 12 
year. One study showed that changes plateaued after 12 months (49). Furthermore, Storer et al, 13 
(58) reported modest changes in LBM (0.7 kg) after 36 months of treatment with a relatively 14 
high dose of T (7.5 mg/day). With regards to treatment delivery vehicle, there were no 15 
differences between the weighted means of the two methods (Gel: 1.35 ± 1.16 kg, Patch: 1.25 ± 16 
1.12 kg) (Fig. 2C).  17 
 18 
[PLEASE INSERT FIGURE 2 ABOUT HERE] 19 
[PLEASE INSERT TABLE 2 ABOUT HERE] 20 
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 1 
Fat mass 2 
In hypogonadal elderly men transdermal TRT treatment reduced FM by a range of 0.1 – 3.0 kg 3 
(Table 2). In individuals with SCI, TRT treatment had no beneficial impact on FM (0.3 kg) (44). 4 
However, relative to the control group, participants on average gained 1.2 kg less FM over the 5 
course of 12 months. Analysis of pooled data suggests larger doses of T (> 5mg) resulted in 6 
greater reductions in FM (Fig. 3A). Interestingly, data from within studies, showed a minimal 7 
impact of increasing dose (5 mg vs. 10 mg); -0.1 ± 1.8 vs. -0.2 ± 1.5 kg (40), -0.90 ± 2.73 vs. -8 
1.05 ± 1.94 kg (49), -0.8 ± 2.4 vs. -0.8 ± 2.0 kg (50). Fig. 3B suggests the weighted mean data 9 
could be skewed by one study, where a 6 mg/day dose of TRT over a longer period of time (36 10 
months) significantly reduced (-3.0 ± 3.7 kg) FM (56). Considering these observations, it 11 
remains unclear whether manipulating dose per se provides additional benefits for reducing FM.  12 
 13 
[PLEASE INSERT FIGURE 3 ABOUT HERE] 14 
 15 
The duration of TRT affected the reduction of FM (Fig. 4), with longer durations demonstrating 16 
greater FM losses. However, within one study, mean changes in FM were greater at 18 than 30 17 
months, -1.57 ± 4.21 kg and -1.30 ± 5.66 kg, respectively (57). Interestingly the method of 18 
delivery appeared to have a slight impact on changes in FM (Gel: -1.00 ± 1.00 kg vs. Patch: - 19 
0.64 ± 0.80 kg) (Fig. 4C). In one study superior reductions (-0.89 kg) in FM with gel was 20 
reported, compared to patch (49). One possible explanation for this difference could be that skin 21 
14 
 
irritation occurred in 66.0% of the participants using the patch compared to 5.5% of participants 1 
using the gel. This consequently altered compliance (65% vs. 93%) and the lower serum T levels 2 
in participants using the patch may explain the diminished reduction in FM (49).  3 
 4 
[PLEASE INSERT FIGURE 4 ABOUT HERE] 5 
The role of testosterone replacement therapy on bone mineral density and metabolism 6 
In addition to its impact on LBM and FM, TRT has also been shown to improve bone mass and 7 
bone mineral density (BMD) (60-63). However, the majority of studies looking at the impact of 8 
TRT on BMD used intramuscular injections, which is outside the scope of this mini-review. A 9 
recent study of almost 300 able-bodied older men with low serum T levels demonstrated that T 10 
gel increased bone density measured by DXA and, volumetric bone density and bone strength by 11 
finite element analysis (64). While these findings demonstrate the efficacy of transdermal TRT, a 12 
recent review that reported that transdermal TRT had very little effect on BMD (65) and findings 13 
from a meta-analysis suggested that TRT administered via intramuscular injections was more 14 
effective at improving BMD than transdermal TRT (66). One explanation for this could be that 15 
changes in BMD are dose-dependent. In rats, Yarrow et al, (67) demonstrated that T dose 16 
dependently prevented hindlimb bone loss 21 days post SCI, with high-dose of T fully 17 
preserving cancellous bone structural characteristics and volumetric BMD. Clinical practice 18 
guidelines recommend a dose of 75 – 100 mg/week for intramuscular TRT and 30 – 70 mg/week 19 
for transdermal (patch) TRT (68, 69). Consequently, larger doses are routinely administered via 20 
the intramuscular route compared to transdermal application. A clinical case series of two 21 
15 
 
patients with SCI did not demonstrate any changes in bone cross-sectional area with 16 months 1 
of transdermal TRT (70). Currently, no studies of TRT in any population have been big enough 2 
to demonstrate reduced fracture risk.  3 
 4 
Findings from a 24-month study demonstrated the return and maintenance of T levels within the 5 
normal range for young adults in men with late-onset hypogonadism resulted in a remarkable 6 
reduction of cardiovascular disease risk factors, which cluster together in patients with metabolic 7 
syndrome (71). The metabolic syndrome is a constellation of component risks which occur at a 8 
heightened frequency in persons with SCI: increased (abdominal) obesity, hypertriglyceridemia, 9 
hyperglycemia and reduced HDL-cholesterol (72-74). In aging hypogonadal men, transdermal 10 
TRT resulted in increased lipid oxidation, whereas no effect was apparent on whole-body insulin 11 
sensitivity (51). In one study transdermal TRT in aging men with T2DM did not change 12 
glycemic control, peripheral insulin sensitivity or endogenous glucose production (52). However, 13 
T2DM was pharmaceutically controlled (metformin) in these participants, which would have 14 
minimized the opportunity to see an effect with TRT on these outcomes. Results from a recent 15 
meta-analysis of observational studies (75) suggested TRTs positive effect on body composition 16 
is what drives observed improvements in glucose and lipid metabolism. 17 
 18 
In persons with SCI, Bauman et al, (76) observed a significant increase in resting energy 19 
expenditure (pre: 1283 ± 246 kcal/day, 12 months: 1410 ± 250 kcal/day) via favorable changes 20 
in LBM with TRT. This increase (Δ 127 kcal/day) has profound implications for persons with 21 
16 
 
SCI. Six months after discontinuing TRT, improvements in LBM and RMR (1393 ± 220) 1 
kcal/day persisted along with elevated high-density lipoprotein cholesterol (HDL-C). However, 2 
these findings need to be replicated in a larger placebo-controlled, double blind trial in men with 3 
SCI. In persons with SCI, independent associations between low T and non-alcoholic fatty liver 4 
disease (NAFLD) have been reported; with a 1% and 3% increased risk of NAFLD for each 5 
decrement of total T (1 ng/dL) and free T (1 pg/mL), respectively (77). Patients in this sample 6 
diagnosed with NAFLD exhibited significantly higher circulating triglyceride concentrations and 7 
homeostatic model assessment of insulin resistance (which reflects hepatic insulin resistance). 8 
Such findings are in keeping with associations between NAFLD and metabolic syndrome 9 
components commonly observed in the able-bodied individuals (78). Steatosis, the first stage of 10 
NAFLD, is the abnormal retention of lipids and represents the liver phenotype of metabolic 11 
syndrome. These findings therefore present another plausible mechanism whereby TRT could 12 
improve specific metabolic syndrome risk factors, although such conclusions remain to be 13 
confirmed by longitudinal TRT trials. 14 
 15 
Safety of testosterone replacement therapy  16 
Despite positive effects of TRT on body composition characteristics, BMD and metabolism; all 17 
trials were underpowered to evaluate safety. Early evidence for the potential of adverse 18 
cardiovascular risk with TRT was provided by the Testosterone in Older Men with Mobility 19 
Limitations (TOM) trial (79), which terminated prematurely.  While data from participants with 20 
mobility impairments might seem relevant to persons with SCI, participants were considerably 21 
older (mean age ± SD; 74 ± 6 years) and the transdermal dose administered was large (10 22 
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mg/day). Since this study, the use of TRT has been further scrutinized, with conflicting messages 1 
regarding its safety. In 2014, a US Food and Drug Administration (FDA) advisory committee 2 
noted insufficient evidence existed to confirm a link between T and cardiovascular events (80). 3 
Yet a year later the same regulatory authority issued a Drug Safety Communication stating that 4 
TRT should only be prescribed to men with low T caused by certain medical conditions due to 5 
the potentially heightened risk/benefit ratio (81). A subsequent review has since challenged this, 6 
stating that TRT is effective and safe when restoring T to within physiological levels in men with 7 
testosterone deficiency, irrespective of its etiology (82). Nevertheless, the FDA has insisted on a 8 
labeling change to inform patients about a possible increased risk of cardiovascular risk (81). 9 
 10 
From a research perspective, clinical trial data and meta-analyses suggest decreased (83-85), no 11 
effect (80, 86, 87) and increased (88-90) risk of cardiovascular events with TRT. However, the 12 
most recent meta-analysis (80) suggested current evidence for cardiovascular risk is of very low 13 
quality due to the high risk of bias, imprecision, and inconsistency between studies. Numerous 14 
studies have also identified age and pre-existing heart disease as factors that increase the risk of 15 
cardiovascular events with TRT (90, 91). With regards to vehicle of administration, studies have 16 
linked an increase in cardiovascular events with oral compared to transdermal TRT (87, 92). 17 
Furthermore, a recent study of a large administrative database revealed that men receiving 18 
testosterone injections had greater cardiovascular risks than those receiving topical testosterone 19 
preparations (93).  However, this evidence contrasts with findings from two meta-analyses, 20 
which suggest a reduction (94) and no difference (92) in the risk of cardiovascular events with 21 
intramuscular injections vs. transdermal TRT. Potential mechanisms for an increased risk of 22 
18 
 
cardiovascular events could be down to increased hemoglobin and hematocrit levels with TRT 1 
(49, 95). Although a retrospective study demonstrated no link between deep vein thrombosis and 2 
pulmonary embolism with TRT (96), a recent study from Australia reported that soon after 3 
starting TRT, the incidence of deep venous thrombosis increased but later returned to close to 4 
background levels (97). Furthermore, hemoglobin and hematocrit values have been reported to 5 
be on the lower end of the normal range in persons with SCI, 1.39 g/L and 40%, respectively 6 
(44). TRT has been shown to significantly increase hemoglobin in men > 65 years with anemia 7 
(98), which may have beneficial implications for symptoms of fatigue and wellbeing. Regular 8 
health screening is advised to test the stability of hematocrit and hemoglobin over time and 9 
check whether values these remain within acceptable limits (hematocrit: < 50%).    10 
 11 
Another safety concern raised regarding TRT is its potential link with prostate cancer. A 2005 12 
meta-analysis of pooled studies (99) suggested significantly higher risks of prostate events, 13 
specifically elevated prostate-specific antigen (PSA) concentrations in men with TRT than the 14 
placebo group. It has been suggested that while TRT may increase PSA, it often remains within 15 
clinically acceptable limits (100) and has not been shown to increase the risk of prostrate cancer 16 
(101, 102). Nevertheless, PSA concentrations should be regularly checked during TRT treatment 17 
and remain under 1.4 ng/ml (67). Logically the use of TRT is contraindicated for men with 18 
prostate cancer or significant benign prostate hyperplasia. Benign and malignant hepatic tumors, 19 
intrahepatic cholestasis, hepatotoxicity, and liver failure have also been reported with TRT (21, 20 
103). However, it appears these unfavorable hepatic effects appear to be associated with oral 21 
forms of T(21). One of the major considerations for using patches as the vehicle of delivery for 22 
19 
 
transdermal T is that they can cause significant skin irritation with prolonged use (42, 43). 1 
Therefore, in men with SCI if patches are worn below the level of injury, we advise regular skin 2 
checks from caregivers as a loss of sensation in the patient might prevent the early detection of 3 
soreness or skin irritation.  4 
 5 
Relevance for persons with spinal cord injury 6 
Hypogonadism in men with SCI has been associated with elevated QT interval variability index 7 
(QTVI) (104) and appears to adversely affect temporal ventricular repolarization (VR) (105). 8 
Elevated QTVI and changes in the synergy of VR can contribute to an increase risk of fatal 9 
arrhythmias (106, 107). Persons with SCI less than 45 years old have approximately a 4-fold 10 
higher rate of cardiac mortality compared to the general population (108). Although the etiology 11 
of increased cardiovascular related mortality is multifactorial in persons with SCI (109-111), low 12 
serum T may be a contributing factor. Indeed, raising T levels into the normal physiological 13 
range with transdermal TRT improved QTVI (104) and normalized ventricular repolarization 14 
dynamics (105), thereby reducing the risk of arrhythmias in men with SCI. However, Budoff et 15 
al, (112) recently demonstrated that transdermal TRT in men with hypogonadism, significantly 16 
increased coronary artery noncalcified plaque volume (measured by coronary computed 17 
tomographic angiography). An increase in noncalcified and total plaque volumes is of clinical 18 
concern because any impairment of the vascular lumen can be considered deleterious (113).  19 
 20 
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In contrast to studies in elderly men, it is interesting that no measurable effect was detected on 1 
FM in persons with SCI (44). This may be due to a reduction in whole-body energy expenditure, 2 
caused by paralysis of lower extremity skeletal muscles and mobility being restricted primarily 3 
to wheelchair use. Bauman et al, (44) speculated that reductions in FM with TRT in persons with 4 
SCI might not occur without a parallel exercise and/or dietary intervention. Although not a 5 
significant increase (P = 0.11), a 1.3 kg increase in leg LBM was observed following 12 months 6 
of TRT in persons with SCI without a concurrent exercise intervention or innervation of 7 
paralyzed muscles. In individuals with SCI it is plausible that TRT effects on LBM in the legs 8 
might be further enhanced with neuromuscular electrical stimulation-induced resistance training 9 
(NMES-RT), a hypothesis that is currently being tested in the Testosterone and Evoked 10 
Resistance Exercise after Spinal Cord Injury (TEREX-SCI) study (114). Improvement in whole 11 
body LMB in persons with SCI equated to 3.5 kg, which is not too dissimilar from the rate of 12 
LBM lost every five years (4 kg) post injury in persons with SCI (115). Skeletal muscle 13 
hypertrophy is a desirable outcome in persons with SCI as skeletal muscle accounts for ~ 70% of 14 
glucose disposal (116). Even increasing LBM by 1.5 kg, which is akin to those reported in 15 
elderly men with TRT (Fig. 1), was associated with improvements in glucose and insulin 16 
concentrations at the end of an oral glucose tolerance test (117). Therefore, increases in LBM 17 
similar to those reported in this review could have dramatic clinical implications for metabolic 18 
regulation in persons with SCI who experience a heightened risk of developing insulin resistance 19 
and T2DM (118, 119). 20 
 21 
Conclusion 22 
21 
 
This mini-review presents evidence for TRT as a potential strategy to aid in the management of 1 
body composition changes and to improve metabolism in persons with SCI. In the absence of 2 
adequate studies conducted in patients with SCI, findings from research conducted using aging 3 
hypogonadal or low serum T men were incorporated to inform the effectiveness of transdermal 4 
TRT for improving body composition parameters. Persons with SCI and aging men exhibit 5 
similar reduced serum T levels and elements of restricted mobility. Relative to placebo 6 
responses, higher doses of T resulted in larger increases in LBM. Importantly, these findings can 7 
be supported by plausible physiological mechanisms. The benefits of TRT must be weighed 8 
against potential risks, and continuous vigilance is required from researchers and clinicians when 9 
administering T. The clinical relevance of a 0.74 kg increase in LBM and 0.33 kg decrease in 10 
FM has with higher (> 5mg/day) vs. lower (≤ 5 mg/day) doses of TRT remains to be established, 11 
along with whether these improvements are worth the potential risks associated with higher 12 
doses. Future research is necessary to develop clinical guidelines pertaining to the specific dose 13 
and duration of TRT treatment and its safety in persons with SCI.  14 
 15 
  16 
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Figure Legends 1 
Fig 1. Weighted mean ± SD changes (Δ) in LBM with different TRT dosages (A). Data was 2 
presented as PLACEBO (n = 730), ≤ 5 mg/day (n = 793) and > 5 mg/day (n = 632). Panel B is a 3 
scatterplot of dose (x-axis) vs. Δ in LBM (y-axis) with a polynomial line of best fit. Fig. 1 was 4 
devised using data from all studies included in Table 1. Weighted means were calculated for 5 
studies where dose of TRT was titrated, providing sufficient information was given within the 6 
study to permit this (44, 51, 52). 7 
 8 
Fig 2. Weighted mean ± SD changes (Δ) in LBM with different TRT durations (A) and vehicle 9 
of delivery (C). Data was presented as 3 months (n = 506), 6 months (n = 496) and ≥ 12 months 10 
(n = 406) and Gel (n = 938) and Patch (n = 307) for panel A and C, respectively. Panel B is a 11 
scatterplot of duration (x-axis) vs. Δ in LBM (y-axis) with a polynomial line of best fit. Fig. 2 12 
was devised using data from studies with TRT dosages ≤ 7.5 mg/day as shorter studies tended to 13 
user higher doses, which would have confounded the analyses. 14 
 15 
Fig. 3. Weighted mean ± SD changes (Δ) in FM with different TRT dosage (A). Data was 16 
presented as PLACEBO (n = 608), ≤ 5 mg/day (n = 915) and > 5 mg/day (n = 526). Panel B is a 17 
scatterplot of dose (x-axis) vs. Δ in FM (y-axis) with a polynomial line of best fit. Fig. 3 was 18 
devised using data from all studies included in Table 2. Weighted means were calculated for 19 
studies where dose of TRT was titrated, providing sufficient information was given within the 20 
study to permit this (44, 51, 52). 21 
31 
 
Fig 4. Weighted mean ± SD changes (Δ) in FM with different TRT durations (A) and vehicle of 1 
delivery (C). Data was presented as 3 months (n = 506), 6 months (n = 496) and ≥ 12 months (n 2 
= 300) and Gel (n = 832) and Patch (n = 307) for panel A and C, respectively. Panel B is a 3 
scatterplot of duration (x-axis) vs. Δ in FM (y-axis) with a polynomial line of best fit. Fig. 4 was 4 
devised using data from studies with TRT dosages ≤ 7.5 mg/day as shorter studies tended to use 5 
higher doses, which would have confounded the analyses. 6 
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